Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -753,651 | -439,950 | -273,911 | -356,734 | -104,359 |
| Depreciation Amortization | 2,710 | 2,019 | 1,098 | 14,071 | 12,646 |
| Accounts payable and accrued liabilities | -12,737 | -8,749 | -11,745 | -18,168 | -18,003 |
| Other Working Capital | -20,719 | -30,091 | -37,166 | -77,046 | -111,530 |
| Other Operating Activity | 197,866 | 86,724 | 117,341 | -401,574 | -445,640 |
| Operating Cash Flow | $-586,531 | $-390,047 | $-204,383 | $-839,451 | $-666,886 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,047,124 | -953,411 | -1,081,681 | -2,101,521 | -3,101,521 |
| PPE Investments | -6,948 | -11,883 | -4,035 | -4,599 | -3,788 |
| Net Acquisitions | N/A | N/A | N/A | 339,750 | 264,824 |
| Sale Of Investment | 200,766 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -2,518 | 0 | 0 | 79 | 0 |
| Investing Cash Flow | $-855,824 | $-965,294 | $-1,085,716 | $-1,766,291 | $-2,840,485 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -51,979 | -51,979 |
| Common Stock Issued | 411,925 | 99,125 | 30,057 | 163,407 | 37,654 |
| Common Stock Repurchased | -208,293 | -208,293 | -208,293 | -1,293,232 | -997,787 |
| Other Financing Activity | -619 | -16,013 | -9,532 | -37,990 | -30,529 |
| Financing Cash Flow | $203,013 | $-125,181 | $-187,768 | $-1,219,794 | $-1,042,641 |
| Exchange Rate Effect | 2,451 | 2,021 | 815 | 747 | 1,236 |
| Beginning Cash Position | 2,725,661 | 2,725,661 | 2,725,661 | 6,550,450 | 6,550,450 |
| End Cash Position | 1,488,770 | 1,247,160 | 1,248,609 | 2,725,661 | 2,001,674 |
| Net Cash Flow | $-1,236,891 | $-1,478,501 | $-1,477,052 | $-3,824,789 | $-4,548,776 |
| Free Cash Flow | |||||
| Operating Cash Flow | -586,531 | -390,047 | -204,383 | -839,451 | -666,886 |
| Capital Expenditure | -6,948 | -11,883 | -4,035 | -4,599 | -3,788 |
| Free Cash Flow | -593,479 | -401,930 | -208,418 | -844,050 | -670,674 |